Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase II Study of Fluconazole for Lymphocutaneous and Visceral Sporotrichosis

This study has been completed.
University of Alabama at Birmingham
Information provided by:
Office of Rare Diseases (ORD) Identifier:
First received: February 24, 2000
Last updated: June 8, 2006
Last verified: April 2000


I. Evaluate the efficacy of fluconazole in patients with lymphocutaneous or visceral sporotrichosis.

Condition Intervention Phase
Drug: fluconazole
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Office of Rare Diseases (ORD):

Estimated Enrollment: 30
Study Start Date: August 1996
Estimated Study Completion Date: August 1996
Detailed Description:


Patients are treated with daily oral fluconazole for up to 24 months. Follow-up continues for at least 1 year.


Ages Eligible for Study:   12 Years and older   (Child, Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


--Disease Characteristics-- Presumptive evidence of sporotrichosis Culture-proven sporotrichosis determined on study Relapsing disease following antifungal therapy eligible if culture positive for Sporothrix schenckii prior to entry No life-threatening disease No central nervous system sporotrichosis --Prior/Concurrent Therapy-- No concurrent drugs known to react with fluconazole No more than 3 days of systemic antifungals for current sporotrichosis episode --Patient Characteristics-- Hepatic: Liver function tests no greater than 5 times normal Other: No HIV infection No pregnant or nursing women

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00004938

Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
University of Alabama at Birmingham
Study Chair: William Dismukes University of Alabama at Birmingham
  More Information

Publications: Identifier: NCT00004938     History of Changes
Other Study ID Numbers: 199/11815  NIAID-MSG-11815 
Study First Received: February 24, 2000
Last Updated: June 8, 2006
Health Authority: United States: Federal Government

Keywords provided by Office of Rare Diseases (ORD):
fungal infection
rare disease

Additional relevant MeSH terms:
Skin Diseases, Infectious
Skin Diseases
Antifungal Agents
Anti-Infective Agents
14-alpha Demethylase Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Steroid Synthesis Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Cytochrome P-450 CYP2C9 Inhibitors
Cytochrome P-450 CYP2C19 Inhibitors processed this record on October 26, 2016